Celdara Medical, LLC today announced that the first DRIVEN Accelerator Hub Participant Company, CairnSurgical, Inc., has closed a Series A investment led by Morningside Group.
Scioto Biosciences and Abigail Wexner Research Institute at Nationwide Children’s Hospital Receive a $2.3 Million Phase II SBIR Grant
Scioto Biosciences, a preclinical stage company developing innovative therapies to transform the delivery of microbiome therapeutics, today announced that they are a recipient of a Phase II SBIR grant from the National Institutes of Health (NIH) for $2.3 million.
Virtici, LLC today announced the launch of an online resource database for biomedical entrepreneurs: http://bioentrepreneurresources.com. This database was developed in collaboration with the DRIVEN Accelerator Hub, a parallel NIH-funded consortium led by Celdara Medical including 10 of the leading research institutions in the Northeast region (NH, VT, ME, DE, and RI).
Virtici, LLC announced today the award of supplemental funds to the ASCEND Accelerator Hub. The ASCEND Accelerator Hub is an NIH-funded consortium led by Virtici and includes 10 of the leading research institutions in the Western States (Alaska, Hawaii, Idaho, Montana, Nevada, New Mexico, and Wyoming).
Rise Therapeutics awarded $2 Million to Develop a Novel, Immunological-Directed Microbiome-based Medicine for Treatment of Sjögren’s Syndrome
Rockville, MD. Rise Therapeutics announced today it was awarded a $2 million, multi-year grant from the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program through the National Institute of Dental and Craniofacial Research (NIDCR). Grant funds will be used to develop a novel, immunologically enhanced probiotic-based therapeutic for the treatment of Sjögren’s syndrome (SS).
Diabetes is a disease of high blood sugar. Diabetic patients also can experience extremely low blood sugar, or hypoglycemia, after fasting, exercising or too large a dose of insulin. If untreated, severe hypoglycemia can lead to coma or even death.